Amyotrophic lateral sclerosis (ALS) is a severe neurodegenerative disease characterized by the degeneration of upper and lower motor neurons. Genetic studies have led, thus far, to the identification of 12 loci and 9 genes for familial ALS (FALS). Although the distribution and impact of superoxide dismutase 1 mutations has been extensively examined for over a decade, the recently identified FALS-associated FUS gene has been less studied. Therefore, we set out to screen our collection of FALS cases for FUS mutations. All 15 exons of FUS were amplified and sequenced in 154 unrelated FALS cases and 475 ethnically matched healthy individuals. One substitution located in the acceptor splice site of intron 14 was identified in all affected members of a large family, causing the skipping of the last 13 amino acids of the protein and the translation of 7 novel amino acids, resulting from the new translation of a part of the 3¢ untranslated region. Our study identified a new splicing mutation in the highly conserved C-terminal of the FUS protein. Thus far most FUS mutations are missenses, and our findings, combined with those of others, confirm the importance of the C-terminal portion of the protein, adding additional support for FUS mutations having a critical role in ALS.
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting the upper and lower motor neurons. Specifically, neurons of the motor cortex, brain stem and spinal cord are progressively involved, causing gradual spasticity and muscle weakness starting in the limbs in 75% of cases and in the bulbar region in 25% of cases. In all, 90% of patients are believed to be sporadic (SALS), without any family history of the disease, while the other 10% of cases are familial (FALS), primarily segregating in an autosomal dominant manner. 1 SALS and FALS patients are clinically indistinguishable, except for the mean age of onset, which is 56 years for SALS, compared with an average of 46 years for FALS. 2 The overall prevalence is 4-6/100 000 and incidence is 1-2/100 000, 3 which make ALS the most common of motor neuron diseases.
Mutations in the copper superoxide dismutase 1 gene were first shown to be ALS causative over 15 years ago and they account for 15-20% of all FALS cases, representing a proportion of 1-2% of all ALS cases. 4 In the last 2 years, the identification of ALS causative mutations in the TAR-DNA-binding protein (TARDBP encoding TDP-43) gene in both SALS and FALS cases 5 and in FUS/TLS encoding FUS, 6,7 thus far mostly but not exclusively in FALS, opened a new era for the investigation of mechanisms underlying the disease. Whereas superoxide dismutase 1 mutations have been reported throughout the full length of the protein, TARDBP and FUS mutations are mostly clustered to specific regions. For TARDBP, most of the mutations identified are in the glycine-rich region encoded by exon 6, and for FUS/TLS, which also contains a glycine-rich region, mutations are mostly in the extreme C-terminal part of the protein. 8 The aim of this study was to evaluate the proportion of FUS mutations in a portion of our FALS cohort and to see if any mutations identified would be clustered to the same region.
The 15 coding exons of FUS were amplified and sequenced in 154 unrelated FALS cases, and only one variant was identified. It is an unreported substitution of an adenine to a cytosine in the acceptor splice site of intron 14 (c.1542-2A4C). The variant was present in six samples of a large ALS family (Figure 1 ) recruited in France: II:5, III:8, IV:1, IV:3, IV:4, and IV:6. Two of those individuals had an ALS phenotype (II:5, III:8), while the four unaffected mutation carriers are in the fourth generation and are younger than the average age of onset of the first ALS symptoms. By carrying the mutation, they confirm that their three affected fathers likely had the substitution. In addition, three mothers married to affected fathers (II:4, III:1 and III:7) were tested and were negative for the mutation. We prepared cDNA using total RNA from the immortalized lymphoblast cell lines of the two affected individuals with the adenine-to-cytosine substitution. These cDNAs were PCR amplified, and two products of 425 and 167 bp were observed on agarose gel (Figure 2a ), demonstrating that the mutant allele was not degraded by nonsense-mediated mRNA decay. The heterozygous sequence trace was analyzed, as well as the separate sequence of the two different alleles after a gel extraction of the two products (Figure 2b be responsible for this new isoform. As this FUS mutation segregates in all affected individuals of the family as well as in the children of deceased affected members, and was not present in 475 control participants, we believe that it is likely responsible for the ALS phenotype observed in this family.
The substitution is located in the RGG domain enriched in arginine-glycine-glycine motifs, where most other FUS mutations were reported. Importantly, truncated proteins were previously observed with the two other major ALS causative genes. [9] [10] [11] But, more interestingly, this is the second splicing mutation reported in FUS, as another one was recently shown to lead to the skipping of exon 14 after the substitution of the adenine located in the acceptor splice site of intron 13. 12 Unfortunately, no clinical information could be retrieved for the family presented in our study, so we were unable to compare the disease evolution caused by our splicing mutation in intron 14 with the splicing mutation in intron 13 reported by DejesusHernandez et al. 12 The splicing mutation identified here removes the last 13 amino acids that partly encode the C-terminal portion of FUS, in which a number of mutations have been associated with ALS. Our finding reinforces the notion that this portion has a key role in the pathology of ALS, most likely by way of affecting the RNAbinding domain it encodes for. In the future, such splicing defect causative mutations may become treatable through drugs or gene therapies aimed at correcting splicing, as explored for a number of disorders. [13] [14] [15] 
